BirchBioMed, Inc. Starts Presentation at LD Micro Main Event
BirchBioMed, Inc. is a biomedical company focused on the commercialization, clinical evaluation and development of proprietary anti-scarring drugs, autoimmune therapeutics/therapies and novel strategies for transplantation. As a University of British Columbia (UBC) spinoff, BirchBioMed holds the exclusive, worldwide pharmaceutical license for two of UBC’s most highly regarded therapeutics, which the university considers to be major medical breakthroughs in the treatment of scarring and certain autoimmune diseases, including Type 1 diabetes and alopecia. For more information, visit the company's website at www.birchbiomed.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network…